A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG: Elafibranor 80 mg
DRUG: Elafibranor 120 mg
DRUG: Placebo Matched to Elafibranor 80 mg
DRUG: Placebo Matched to Elafibranor 120 mg

Sponsor

Ipsen